Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release
Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key
Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization29.1.2026 14:30:00 CET | Press release
Innodata's data engineering and annotation capabilities support Palantir's expanding AI platform deployments for event analytics NEW YORK, NY / ACCESS Newswire / January 29, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it has been selected to provide high-quality training data and data engineering services to Palantir Technologies (Nasdaq:PLTR), supporting Palantir's AI-enabled platforms for rodeo event analysis. In support of Palantir's partnership with rodeo operations, Innodata is now further empowering these customers by providing them with specialized annotation and data engineering for thousands of hours of rodeo video footage. This work enables computer vision models to detect animals, riders, and skeleton joints, allowing for the automated calculation and display of performance metrics in bull riding, bronc riding, bareback riding and barrel racing. Innodata will be providing specialized annotation, multimodal data engineering, and generative-AI workflow support for
Sadie Launches Cloudbeds Integration to Automate Guest Calls and Reservation Management with Voice AI28.1.2026 17:25:00 CET | Press release
MONTRÉAL, QUEBEC / ACCESS Newswire / January 28, 2026 / Sadie, the voice AI agent for the hospitality industry, today announced a new integration with Cloudbeds, the hospitality industry's leading unified platform, enabling hotels to automate guest calls while increasing direct bookings and freeing staff to focus on on-property service. Through the integration, Cloudbeds-powered hotels can deploy Sadie as an intelligent voice agent that answers calls instantly, shares real-time rates and availability, and creates and manages reservations directly within the Cloudbeds platform. Designed as an always-on extension of the front desk, Sadie ensures guest calls are answered instantly, day or night. From sharing real-time rates and availability to creating and modifying reservations, handling service requests, and assisting with overnight room lockouts, Sadie delivers immediate, multilingual support for both guests and hotel teams. By handling high-volume and after-hours calls, Sadie reduces
Power to Hydrogen Appoints David Bow as Chief Strategy Officer to Scale International Expansion28.1.2026 15:00:00 CET | Press release
Industry Veteran Brings 25+ Years Of Senior Leadership In Hydrogen And Industrial Decarbonization COLUMBUS, OH / ACCESS Newswire / January 28, 2026 / Power to Hydrogen (P2H2), a developer of industrial-scale anion exchange membrane (AEM) electrolyzers designed for low-cost green hydrogen production, today announced that industry veteran David Bow has joined the company as Chief Strategy Officer. Bow will lead P2H2's corporate and commercial strategy as the company expands its industrial deployments and scales its go-to-market efforts in North America and Europe. His scope includes strategic partnerships, market entry and segmentation, commercial growth priorities, and alignment of product roadmap and validation plans with customer and financing requirements. Bow brings more than 25 years of senior leadership experience across hydrogen and industrial energy, including executive roles spanning commercialization, strategy, and scaling. He previously led Plug Power's Electrolyzer Solutions
GoodData Brings Faster BI Modernization to Make Analytics AI-Ready28.1.2026 15:00:00 CET | Press release
Modernize legacy BI without disruption. Refactor business logic into a governed semantic layer while keeping dashboards online. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 28, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today introduced AI-driven BI modernization, a new approach that helps organizations move off legacy BI faster while preserving critical reporting workflows. Early outcomes teams can expect AI-driven BI modernization separates business logic from dashboards and standardizes it in a governed semantic layer. This improves performance today and creates a stronger baseline for AI-driven use cases tomorrow. Expected results include: 2-5× faster iteration cycles for delivering new analytics Dashboards that load up to 10× faster by removing inefficient calculations and duplication Consistent, reusable metrics governed centrally and applied across teams and tools AI-ready analytics with clean, standardized logic that AI agents and aut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom